Gufic BioSciences Ltd(GUFICBIO)

NSE: GUFICBIOBSE: 509079

₹ 392.6-0.49%refreshed 23 Oct, 03:50 pm ISTMarket cap: ₹ 3,937 crWebsite: www.gufic.comUpdated: 26 Oct 2026

About

Gufic BioSciences is an Indian pharmaceutical company specialising in lyophilized and complex injectables, with nine therapy-focused divisions spanning critical care, fertility, aesthetics, neurology, nutraceuticals and women's health. It reported revenue of Rs 944.01 Cr in FY26 and consistently ranks among the top 100 pharmaceutical companies in India. Stunnox, its botulinum toxin A brand, holds the No. 2 position in India by blended market share.^[1][2]

Revenue by geography

India revenue was Rs 654.49 Cr in FY25 vs Rs 718.52 Cr in FY24.^[2][3]
Europe revenue was Rs 61.78 Cr in FY25 vs Rs 29.64 Cr in FY24; Asia was Rs 49.55 Cr vs Rs 36.3 Cr.^[2][3]
Africa revenue was Rs 24.14 Cr in FY25 vs Rs 9.87 Cr in FY24; South America Rs 19.47 Cr vs Rs 1.89 Cr; North America Rs 9.75 Cr vs Rs 10.24 Cr.^[2][3]
Key markets named in the FY25 annual report include India, Germany, Switzerland, South Africa, Russia, Canada, Brazil and Europe.^[2]

Business divisions

As of FY25 the business is organised into nine divisions, each with a distinct therapeutic focus; portfolio spans herbal formulations, antibiotics, antifungals, cardiology, infertility, antivirals and PPIs.^[2]
Criticare cluster (Critimax, Mycocare, Primacare, Sparsh) serves critical-care injectables, with an addressable opportunity of ₨22,000 to ₨24,000 Crores for current molecules (FY25 report).^[2]
Sparsh, the critical-care hospital division, completed a shift from direct-to-hospital billing to a CFA/stockist-led channel during FY26.^[4]
Ferticare cluster (Ferticare, Fertimax) targets a ₨4500 crores fertility market; it reported >50% YoY YTD growth in H1 FY26, with Puregraf on track for ~Rs 25 Cr per annum.^[2][5]
Zenova covers women's health; it posted strong double-digit YoY growth in Q2 FY26 with an Rx-to-injectable ratio of 70:30.^[5]
Aesthaderm and NeuroCare market Stunnox botulinum toxin A; Aesthaderm hit all-time-high monthly sales in Q2 FY26 with 1,000+ practitioners recommending Stunnox.^[5]
The Healthcare nutraceutical division is built around the Sallaki (Boswellia serrata) platform, with brands Nucart-OA/VG, Bocomo Forte, Smashit, Imunocin and Aswal Plus (FY25).^[2]

Branded products

Stunnox holds the No. 2 position in India by blended market share on IQVIA data, with all-time-high monthly sales in FY26.^[4]
Gufic has a DCGI-approved immunomodulatory therapy for sepsis, described as first-to-market (FY25 report).^[2]
Zenova's Stretch Nil is described as the only pregnancy-dedicated stretch-mark solution in the prescription channel; DD1 and Stretch Nil drove QoQ growth in Q2 FY26.^[2][5]
AWABAC, a monobactam and beta-lactamase inhibitor combination for MDR gram-negative infections, launched in Q1 FY27 on innovator patent expiry.^[6]

Manufacturing operations

Operates automated lyophilization facilities in Navsari, Gujarat and Indore, Madhya Pradesh; EU-GMP certified Navsari Unit II is the backbone of current production (FY25).^[2]
Indore had 203 State FDA product permissions as of Q1 FY27, with tech transfer completed for 40 products and 27 more under development.^[6]
Indore utilisation reached ~30-35% in Q1 FY27 vs ~20-25% in the prior quarter; management targets 40-45% by end of FY27.^[6]
EU GMP and UK MHRA audit of Indore was completed in Q1 FY27, with certification awaited; USFDA inspection of Indore is targeted for FY29.^[6][4]
Navsari Unit-II CMO clients are being migrated to Indore, freeing Navsari capacity for exports.^[4]
An in-house extraction facility and dedicated nutra/herbal manufacturing give control of sourcing and standardisation (FY25).^[2]

Capacity and pipeline numbers

Peak revenue from Navsari and Indore combined at the current mix is estimated at Rs 1,600-Rs 2,000 Cr (Q1 FY27).^[6]
At 75%+ utilisation, Indore alone can generate about Rs 675-700 Cr of revenue (Q4 FY26).^[4]
17 active or pipeline clinical studies were running as of Q1 FY27.^[6]
Launched 30+ generic products in FY24, with ~25 poised for commercialisation in FY25 and 70+ under development.^[3]

International and contract manufacturing

Gufic Ireland holds EU Marketing Authorisations and secured approvals in 8 countries in Q1 FY27.^[6]
A UK NHS tender was secured, with supplies from Navsari starting in FY'25 - 26.^[2]
In Q1 FY27 Gufic signed a CMO and licensing deal with a North American counterparty and received first CMO orders from Australia.^[6]
GLP-1 CMO partnership with Hetero began in Q1 FY27 after Hetero's semaglutide approvals in May 2026; meaningful revenue expected from Q2/Q3 FY27.^[6]
A major global health organisation partnered on a complex injectable asset, giving access to 109 public health markets (Q3 FY26).^[7]
In H1 FY26, 24 product and facility approvals were secured across South Africa, Colombia, Portugal, Myanmar, Sri Lanka, Cambodia, Thailand and Lithuania.^[5]

R&D and new products

R&D pipeline includes recombinant hormone biosimilars, first-of-their-kind toxins and oral vaccine research; platforms include liposomal, microspheres, suspensions and RTU solutions (FY25).^[2]
Depot/microsphere suite and lipid-based antifungal lines are being set up within existing Indore capex, targeted to be operational during FY27.^[6]
Revanesse dermal filler in-licensed from Prollenium (Canada) for India; launch targeted December 2026 or January 2027 in an estimated Rs 200 Cr market.^[6]
Stunnox/Zarbot export registrations are in progress in Southeast Asia and Africa, with 12-18 month timelines per geography (Q1 FY27).^[6]
Two complex injectables were filed in 18 EU countries via Gufic Ireland, targeting 5-10% share over 3-5 years (Q4 FY26).^[4]
Selvax platform: SVX-3001 anti-CD40 agonist antibody is in advanced cell-line development; a canine Phase I trial showed a 68.4% clinical benefit rate (Q3 FY26).^[7]
NaproPure, an NSAID pain-management range, was targeted for launch in Q2 FY27.^[6]

Recent developments

Sparsh completed a full quarter on its rebuilt CFA/stockist channel in Q1 FY27, expanding into Northeast India and Jammu & Kashmir.^[6]
SAP S4 HANA ERP implementation was underway across all departments as of Q4 FY26.^[4]

Market Cap

₹3,937 Cr

High / Low

₹466 / 268

Stock P/E

53.6

Price / Book

5.9

Book Value

₹66

EPS

₹6.4

No. of Shares

10.03 Cr

ROCE

12.3%

ROE

10.1%

OPM

13.0%

Debt / Equity

0.58

Sales

₹944 Cr

Net Profit

₹64 Cr

Promoter holding

72.5%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials

Gufic BioSciences Ltd(GUFICBIO)

About

Revenue by geography

Business divisions

Branded products

Manufacturing operations

Capacity and pipeline numbers

International and contract manufacturing

R&D and new products

Recent developments

Signal history

The analysis Screener can't give you

AI Deep Dive

Verdict

Company data

Product Segments

Corporate Actions